$CARSGEN-B(02171)$ is accelera

$CARSGEN-B(02171)$ is accelerating its focus on off-the-shelf CAR-T cell therapy, with a subsidiary valued at an impressive 1 billion RMB.

The company’s first commercialized product, Zevorcabtagene Autoleucel, has generated 39.4 million RMB in sales, and an application for the world’s first CAR-T therapy targeting solid tumors is set to be submitted in the first half of the year. This marks a crucial milestone for the company and could be a game-changer in the industry.

Investors should keep a close eye on CARsgen’s R&D progress—its innovations hold great promise!

Winning Trades

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":418362968224128,"tweetId":"418362968224128","gmtCreate":1743147192579,"gmtModify":1743148183879,"author":{"id":9000000000000521,"idStr":"9000000000000521","authorId":9000000000000521,"authorIdStr":"9000000000000521","name":"KittyBruno","avatar":"https://static.tigerbbs.com/55e526bf56359c8153d15df97d3245b8","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":177,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/8cf218dabb195af7df7f8a5aad2d10e4","width":"767","height":"1280"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/8cf218dabb195af7df7f8a5aad2d10e4","width":"767","height":"1280"}],"html":"<html><head></head><body> <a data-mention-id=\"02171\" class=\"teditor-mention\" data-mention-name=\"CARSGEN-B\" href=\"https://ttm.financial/S/02171\">$CARSGEN-B(02171)$</a> is accelerating its focus on off-the-shelf CAR-T cell therapy, with a subsidiary valued at an impressive 1 billion RMB. The company’s first commercialized product, Zevorcabtagene Autoleucel, has generated 39.4 million RMB in sales, and an application for the world’s first CAR-T therapy targeting solid tumors is set to be submitted in the first half of the year. This marks a crucial milestone for the company and could be a game-changer in the industry. Investors should keep a close eye on CARsgen’s R&amp;D progress—its innovations hold great promise!<img src=\"https://community-static.tradeup.com/news/8cf218dabb195af7df7f8a5aad2d10e4\" tg-width=\"767\" tg-height=\"1280\"></body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"02171\" class=\"teditor-mention\" data-mention-name=\"CARSGEN-B\" href=\"https://ttm.financial/S/02171\">$CARSGEN-B(02171)$</a> is accelerating its focus on off-the-shelf CAR-T cell therapy, with a subsidiary valued at an impressive 1 billion RMB. The company’s first commercialized product, Zevorcabtagene Autoleucel, has generated 39.4 million RMB in sales, and an application for the world’s first CAR-T therapy targeting solid tumors is set to be submitted in the first half of the year. This marks a crucial milestone for the company and could be a game-changer in the industry. Investors should keep a close eye on CARsgen’s R&amp;D progress—its innovations hold great promise!<img src=\"https://community-static.tradeup.com/news/8cf218dabb195af7df7f8a5aad2d10e4\" tg-width=\"767\" tg-height=\"1280\"></body></html>","text":"$CARSGEN-B(02171)$ is accelerating its focus on off-the-shelf CAR-T cell therapy, with a subsidiary valued at an impressive 1 billion RMB. The company’s first commercialized product, Zevorcabtagene Autoleucel, has generated 39.4 million RMB in sales, and an application for the world’s first CAR-T therapy targeting solid tumors is set to be submitted in the first half of the year. This marks a crucial milestone for the company and could be a game-changer in the industry. Investors should keep a close eye on CARsgen’s R&D progress—its innovations hold great promise!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/418362968224128","repostId":0,"isVote":1,"tweetType":1,"viewCount":115,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02171"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":483,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/418362968224128"}